EGF and non-small cell lung carcinoma: CIMAvax-EGF, a vaccine targeting epidermal growth factor (EGF), significantly prolonged median OS (12.43 vs. 9.43 months, p = 0.036) as maintenance therapy in a phase III trial for NSCLC [67].